FIELD: biotechnology.
SUBSTANCE: the present invention relates to biotechnology and medicine, namely to a method for obtaining a lyophilized composition consisting of an isolated microorganism belonging to Mycobacterium tuberculosis, characterized by the presence of the PhoP− phenotype as a result of inactivation by genetic deletion of the Rv0757 gene and deletion of the second gene, Rv2930 (fadD26), preventing PDIM production (PDIM− phenotype) (MTBVAC strain).
EFFECT: invention makes it possible to obtain a lyophilized composition and effectively use it as a prophylactic agent for individuals at risk of M. tuberculosis infection or at risk of developing tuberculosis, or as secondary agents for the treatment of patients with tuberculosis infection.
1 cl, 11 dwg, 15 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUBERCULOUS VACCINE | 2007 |
|
RU2443773C2 |
| STRAIN OF MYCOBACTERIUM TUBERCULOSIS BN FOR MODELLING LATENT TUBERCULOSIS INFECTION | 2021 |
|
RU2760751C1 |
| IMMUNOTHERAPEUTIC AGENT FOR PRIMARY PREVENTION OF TUBERCULOSIS | 2009 |
|
RU2544125C2 |
| POLYANTIGENIC VACCINE FOR PREVENTING AND ADJUNCTIVE TREATMENT OF TUBERCULOSIS | 2019 |
|
RU2724896C1 |
| RECOMBINANT BCG OVEREXPRESSING PhoP-PhoR | 2017 |
|
RU2760580C2 |
| VACCINE COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF TUBERCULOSIS INFECTION AND GENETIC CONSTRUCTIONS FOR PREPARING ACTING COMPONENTS OF THIS COMPOSITION | 2003 |
|
RU2262351C1 |
| PREPARATIONS, CONTAINING HUMAN ANTIBODIES APPLIED IN TREATMENT OF MICROBACTERIAL INFECTIONS | 2003 |
|
RU2350352C2 |
| PREVENTIVE ANTI-TUBERCULOSIS VACCINE | 2007 |
|
RU2526910C2 |
| ANTIBODY AGAINST LIPOARABINOMANNAN AND IMMUNOASSAY OF INFECTIONS CAUSED BY ACID-FAST BACILLI, USING ANTIBODY | 2013 |
|
RU2588480C2 |
| IMMUNOGENIC COMPOSITION (VERSIONS) BASED ON RECOMBINANT INTRACELLULAR PATHOGEN | 2003 |
|
RU2337707C2 |
